Physician profile
York C Yang
NPI 1649317058
$2,710.42
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $638 · 2020: $620 · 2021: $1,453.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $474.46 | 2019-2021 | |
| Novo Nordisk INC | $287.08 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $252.48 | 2019-2021 | |
| Lilly USA, LLC | $230.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $203.53 | 2019-2021 | |
| Abbvie INC. | $203.40 | 2021 | |
| Astellas Pharma US INC | $138.71 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $120.90 | 2019-2021 | |
| Amgen INC. | $98.43 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.36 | 2020-2021 | |
| Allergan, INC. | $79.93 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $73.28 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $70.97 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.25 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $53.86 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $52.70 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $50.95 | 2019-2021 | |
| Genentech USA, INC. | $43.11 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $23.95 | 2021 | |
| Abbott Laboratories | $18.24 | 2021 | |
| Bausch Health US, LLC | $17.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.44 | 2021 | |
| Eisai INC. | $16.50 | 2021 | |
| Ibsa Pharma INC. | $14.46 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.09 | 2021 | |
| Amarin Pharma, INC. | $10.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw York Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.